文献速递膀胱癌与上尿路尿路上皮癌

FGFR3改变状态与局部晚期及转移性尿路上皮癌铂类化疗敏感性差异相关

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
PubMed 文献 · Eur Urol · 2020-08-01

该回顾性研究比较了FGFR3改变与野生型患者在三个队列中对铂类化疗的反应。在MIBC新辅助化疗队列中,FGFR3改变与较短的无复发生存相关(HR 2.74,p=0.044),且无一例达到病理完全缓解。在转移性队列中,FGFR3改变者应答率较低(37% vs 49%,p=0.056),但PFS和OS无显著差异。

要点

  • FGFR3改变在MIBC新辅助化疗患者中与较短RFS相关(HR 2.74,p=0.044)。
  • 转移性队列中FGFR3改变者应答率37% vs 49%(p=0.056),PFS和OS无显著差异。
  • FGFR3改变者肺转移和非区域淋巴结病变发生率更高。

核心结论

  • FGFR3状态与铂类化疗应答较低相关,可能提示对FGFR3改变尿路上皮癌围手术期探索非化疗方案。
  • FGFR3状态对转移性尿路上皮癌化疗应答无显著影响。

研究设计与样本

  • 回顾性综述和比较,包括接受新辅助化疗的MIBC患者(n=72)、接受一线铂类化疗的mUC患者(M1队列,FGFR3alt n=27,FGFR3wt n=81)以及来自TCGA的MIBC患者。

主要发现

  • NAC队列中9/72(13%)有FGFR3alt,无一例病理完全缓解,3例残留非MIBC(原位癌n=1;pT1 n=2)。
  • FGFR3alt与较短RFS相关(HR 2.74;p=0.044),但与OS无关。
  • TCGA接受辅助化疗的患者(n=74)中,FGFR3alt患者RFS也较短。
  • 化疗初治TCGA患者中,FGFR3alt与较长RFS和OS相关。
  • M1队列中FGFR3alt与较高肺转移和非区域淋巴结病变率相关,应答率较低(37% vs 49%;p=0.056),PFS和OS无显著差异。

关键数值与推荐

  • NAC队列FGFR3alt 9/72(13%),无一例病理完全缓解。
  • FGFR3alt与较短RFS相关(HR 2.74;p=0.044)。
  • M1队列应答率FGFR3alt 37% vs FGFR3wt 49%(p=0.056)。

临床怎么用

  • FGFR3状态可能有助于识别铂类化疗应答较低的MIBC患者,考虑非化疗围手术期方案。
  • 转移性尿路上皮癌中FGFR3状态不影响化疗选择。

局限性

  • 回顾性研究设计。
  • 样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs). OBJECTIVE: To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC. DESIGN, SETTING, AND PARTICIPANTS: The authors conducted a retrospective review and comparison of patients having (1) MIBC treated with neoadjuvant chemotherapy (NAC), (2) mUC treated with first-line platinum-based chemotherapy (M1 cohort), and (3) MIBC who were from The Cancer Genome Atlas (TCGA). INTERVENTION: Platinum-based chemotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathologic response, recurrence-free (RFS) or progression-free (PFS) survival, and overall survival (OS) were compared between patients with FGFR3 alteration (FGFR3alt) and those without it (FGFR3wild type [FGFR3wt]) in the three cohorts. RESULTS AND LIMITATIONS: Nine of 72 NAC patients (13%) had FGFR3alt, of whom none had pathologic complete response and three had residual non-MIBC (carcinoma in situ, n = 1; pT1, n = 2). FGFR3alt was associated with shorter RFS (hazard ratio, 2.74; p = 0.044) but not OS. Among TCGA patients who underwent adjuvant chemotherapy (n = 74), FGFR3alt patients had shorter RFS as well. Conversely, among chemotherapy-naive TCGA patients, FGFR3alt was associated with longer RFS and OS. In the M1 cohort (FGFR3alt, n = 27; FGFR3wt, n = 81), FGFR3alt was associated with higher rates of pulmonary metastases and nonregional lymphadenopathy. Despite lower response rates among FGFR3alt patients (37% vs 49%; p = 0.056), PFS and OS were not significantly different from FGFR3wt patients. CONCLUSIONS: FGFR3 status is associated with lower responses to platinum-based chemotherapy, which may prompt exploration of nonchemotherapeutic approaches for perioperative management of FGFR3alt urothelial cancers. PATIENT SUMMARY: Approximately 15% of bladder cancers harbor mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Our findings suggest that FGFR3 mutations might be associated with lower responses and shorter time to recurrence among patients with muscle-invasive bladder cancer who received perioperative platinum-based chemotherapy. FGFR3 status does not significantly impact response to chemotherapy among those with metastatic urothelial cancers.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Teo MY, Mota JM, Whiting KA, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol. 2020. PMID: 32753285. doi:10.1016/j.eururo.2020.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。